merck keytruda - Search News

News

Merck Expects $200 Million Tariff Hit

Merck Expects $200 Million Hit From Current US Tariffs

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China.

The Wall Street Journal on MSN · 2d

Merck Cuts 2025 Outlook on Tariffs, Charges

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 adjusted earnings projection, partly to account for recently imposed tariffs.

Crain's New York Business · 2d

Merck expects $200M tariff hit amid Gardasil fallout

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results beat estimates. First quarter sales were $15.5 billion, above the $15.3 billion analysts had predicted. Adjusted earnings of $2.22 per share outpaced expectations of $2.13 a share.

Merck Faces Patent Lawsuit Over Easier-to-Use Keytruda

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

STAT1d

Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Fierce Pharma2d

Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

BMO says Keytruda ‘still reigns’ after ivonescimab survival data

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

BioPharma Dive1d

Halozyme sues Merck; FDA blames cuts for Vanda delay

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

Fierce Pharma2d

Merck ‘willing to work’ with Trump administration on price gap between US, international medicines

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Halozyme sues Merck for patent infringement over subcutaneous Keytruda

Halozyme (HALO) filed a patent infringement lawsuit against Merck (MRK) in U.S. District Court in New Jersey. Halozyme believes the ...

Zacks.com on MSN2d

Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut

MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase ...

Investor's Business Daily on MSN3d

BioNTech Surges On Summit's Coattails. But Can They Take On Merck?

BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.Summit's Akeso-partnered drug, ivonescimab, works by blocking ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results